SOURCE: Cavit Sciences, Inc.

September 18, 2007 08:52 ET

Cavit Sciences, Inc. Announces Supplement Manufacturing and Distribution Update

DELRAY BEACH, FL--(Marketwire - September 18, 2007) - Cavit Sciences, Inc. ("Cavit") (OTCBB: CVIT) today announced the status of the Company's supplement line.

Cavit's team has been conducting meetings and discussions with various manufacturers and distributors supplying major volume markets for our supplement products. We have identified the optimal parties to work with and are in the process of negotiating and finalizing agreements.

The manufacturer is in close proximity to the U.S., but the cost will be 1/3 of the cost to manufacture in the U.S. Quality control is the highest priority. The manufacturer will operate as a complete fulfillment center. Cavit's proprietary formulations will be included in the supplement products, packaged, labeled and shipped to worldwide exclusive distributors directly from the manufacturer. The manufacturer has a high-quality experienced workforce and a facility that can accommodate our future growth.

The manufacturer has established distribution channels for all of Europe and Central America. In addition, we have met with and are in discussions with exclusive distributors for all of China, South America and Mexico. Our supplements will have immediate markets and distribution channels in place. Cavit's supplement formulas are the result of almost 50 years of research conducted by Dr. Joseph P. D'Angelo along with a team of medical doctors and biologists whose research helped develop Cavit's proprietary formulas. Superior results have been attained by individuals through the use of Cavit's products.

Cavit's supplement line offers individuals the logical and cost effective alternative to expensive drugs with adverse side effects promoted by major drug firms and to the products of other supplement companies that supply only a portion of the optimum ingredients at less than the optimum dosage.

Cavit fulfills the demands and needs of the worldwide population concerned with enhancing specific conditions, better health and improving the quality of their lives. The global supplement market exceeds $67 billion annually and Cavit is positioning its products to accommodate this market.

Cavit Sciences, Inc. ("Cavit") is a biotechnology company engaged in developing treatments and prevention for cancer, viral infections and related diseases. Additional information regarding our drug development, supplement line and Company information is available on the Company's website at:

Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements made by Cavit. These factors include, but are not limited to: (i) the ability of Cavit to successfully raise financing, (ii) the ability of Cavit to finalize its manufacturing and distribution facilities, and (iii) the ability of Cavit to successfully commercialize its products in certain markets. Additional factors that would cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Cavit's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" for Cavit on Form 10K-SB filed on April 12, 2007 and its subsequently filed Forms 10-QSB.

Contact Information